

Special Issue

Molecular and Histopathological Background of Diabetic Neuropathy

Message from the Guest Editor

Although diabetic neuropathy has been known about for a long time, the complex pathogenesis and molecular backgrounds still need further investigation. Chronic hyperglycaemia differently affects various parts of the nervous system. Not only neurons, but also the neuronal microenvironment, like glia cells, microvessels or the elements of the immune system, can be altered by the diabetic state. Furthermore, hyperglycaemic state damages are not exclusive to the peripheral nervous system, which suggests the necessity to understand the function of the [central nervous system](#) in the development of diabetic peripheral neuropathy. The aim of this Special Issue is to highlight diabetes-related neurological alterations both in patients and animal models. Original research articles and review articles focusing on different forms of neuropathy in all type of diabetes are welcome. The understanding of different pathways of chronic hyperglycaemia-related neuropathy will help to develop new diagnostic and therapeutic strategies which can prevent or help in diabetes-related conditions.

Guest Editor

Dr. Mária Bagyánszki

Department of Physiology, Anatomy and Neuroscience, University of Szeged, Szeged, Hungary

Deadline for manuscript submissions

30 November 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/237112

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).